Figure 3

CD155 is highly expressed in cancer cells and primary tumors. (a) Lysates from normal and cancer-derived cell lines were immunoblotted for CD155. CD155 expression was elevated in fibrosarcoma cells (HT1080) vs. normal fibroblasts (Hs27) and also in glioblastoma cells (U87MG) vs. normal human astrocytes (NHA). Antibody specificity is demonstrated using HT1080 cells in which CD155 expression is knocked down by RNAi. β-actin is shown as a loading control. (b) CD155 protein expression was examined by immunocytochemistry across a panel of normal and cancer tissue samples. In normal tissue we observed moderate staining in kidney, plasma cells, liver, lung, theca interna of the ovary, and testis. No staining was observed in normal adrenal, bladder, brain, breast, colon, heart, pancreas, placenta, prostate, skin, skeletal muscle, small intestine epithelium, spleen, stomach, thymus, thyroid, or uterus. In cancer tissue, significant staining was observed in prostate, renal cell, and pancreatic carcinomas as well as in colon, non-small cell lung, ovarian, and breast carcinomas. (c) High CD155 protein expression was also observed in glioblastoma tumor tissue. Two types of staining were evident: scattered positive cells (arrows) in a primarily negative sample, or diffuse staining across many cells in a sample.